Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Swiss Franc: Gains in focus against US Dollar near 0.8200 – UOB

Swiss Franc: Gains in focus against US Dollar near 0.8200 – UOB

FXStreetFXStreet2026/10/21 08:12

UOB strategists Quek Ser Leang and Lee Sue Ann observe that USD/CHF fell sharply before rebounding, leaving overall momentum subdued. They expect intraday trading to remain range-bound, but their 1–3 week view still favours gradual Dollar weakness toward 0.8200, as long as prices stay below a revised strong resistance level, while the longer-term outlook allows for a moderate rebound.

Dollar-Swiss capped with room to ease

"24-HOUR VIEW: We indicated yesterday that “the slight increase in upward momentum suggests USD could edge higher today, but any advance should stay within a 0.8240/0.8285 range.” The subsequent price movements did not unfold as expected. USD fell sharply, but briefly, to 0.8220 and then rebounded to close at 0.8246 (-0.23%). The price movements did not lead to any increase in downward momentum. Today, we expect USD to trade in a range, most likely between 0.8225 and 0.8270."

"1-3 WEEKS VIEW: Last Friday (16 Oct, spot at 0.8280), we highlighted that “downward momentum is building and if USD closes below 0.8245, it could decline toward 0.8225.” After USD subsequently fell to a low of 0.8215, we highlighted on Monday (19 Oct, spot at 0.8240) that USD “could decline further to 0.8200.” Although USD has not been able to make much headway on the downside since then, we will continue to hold the same view as long as USD holds below 0.8290 (‘strong resistance’ level previously at 0.8300)."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.